Dissolving Microneedles for Transdermal Delivery of Melatonin: Fabrication, Characterization, and In Vivo Pharmacokinetic Evaluation in Mice
ACS Applied Bio Materials · 17.06.2026
DOI: 10.1021/acsabm.6c00235 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 17.06.2026. Verfasst von Hadar Nimni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, Azrieli College of Engineering Jerusalem, Jerusalem 9103501, Israel. Hauptthemen laut MEDLINE: Melatonin, Biocompatible Materials. Die Arbeit nennt 70 Literaturangaben. Gefördert von: Azrieli College of Engineering Jerusalem.
Abstract (Originalsprache)
Insomnia is a common physiological and psychological disorder characterized by difficulty falling or staying asleep, which negatively impacts daily functioning. Oral melatonin (MEL) is commonly used to treat insomnia and other sleep-related disorders. However, MEL has low bioavailability due to extensive first-pass metabolism and poor aqueous solubility, and its onset of action is slow. Dissolving microneedles (MNs) represent a promising minimally invasive approach to overcome these drawbacks by enhancing transdermal drug permeation and enabling systemic delivery while circumventing the gastrointestinal tract. In this study, different dissolving MN arrays composed of hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidone (PVP) were fabricated using solvent casting and vacuum-assisted micromolding techniques. Among the tested formulations, 10% (w/v) HPMC and 10% (w/v) PVP-based formulation demonstrated favorable mechanical strength and insertion capability. MEL was successfully loaded into the MN shafts of the lead formulation with a drug loading of 1.83 ± 0.05 mg per MN patch. FTIR and DSC analyses confirmed the molecular dispersion of MEL within the polymeric matrix. In vitro release studies revealed rapid dissolution with approximately 87% of melatonin released within 60 min, whereas ex vivo tests on porcine skin showed complete microneedle dissolution within 3 min. In vivo pharmacokinetic studies in mice revealed rapid systemic absorption following MEL MN application and a prolonged elimination half-life. MEL also penetrated the central nervous system (CNS), reaching a C max of 6.08 ± 3.65 ng/g and exhibiting a prolonged residence time in the brain. Taken together, MEL MNs hold promise as a viable transdermal delivery modality. However, further investigation is warranted to comprehensively evaluate their therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering, Azrieli College of Engineering Jerusalem, Jerusalem 9103501, Israel.
- The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
ORCID-Profile: Vladislav Nesterenko, Aiman Abu Ammar
Förderung
- Azrieli College of Engineering Jerusalem
Zitieren
APA
Nimni, H., Nesterenko, V., Bader, N., Sheeni, Y., Shekh-Ahmad, T., & Abu Ammar, A. (2026). Dissolving Microneedles for Transdermal Delivery of Melatonin: Fabrication, Characterization, and In Vivo Pharmacokinetic Evaluation in Mice. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.6c00235
Vancouver
Nimni H, Nesterenko V, Bader N, Sheeni Y, Shekh-Ahmad T, Abu Ammar A. Dissolving Microneedles for Transdermal Delivery of Melatonin: Fabrication, Characterization, and In Vivo Pharmacokinetic Evaluation in Mice. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.6c00235
BibTeX
@article{Nimni2026,
author = {Nimni, Hadar and Nesterenko, Vladislav and Bader, Nadeen and Sheeni, Yara and Shekh-Ahmad, Tawfeeq and Abu Ammar, Aiman},
title = {Dissolving Microneedles for Transdermal Delivery of Melatonin: Fabrication, Characterization, and In Vivo Pharmacokinetic Evaluation in Mice},
journal = {ACS Applied Bio Materials},
year = {2026},
doi = {10.1021/acsabm.6c00235}
}
EUVIMED